On January 5, 2022, amendments came into force amending the Food and Drug Regulations to allow practitioners to request access to restricted drugs through the Special Access Program (SAP), which was previously prohibited. Restricted drugs are controlled substances that are listed in the Schedule to Part J of the Food and Drug Regulations which includes, for example, certain amphetamines and lysergic acid diethylamide (LSD). Health Canada revised its Special Access Program for drugs: Guidance document for industry and practitioners to reflect these amendments. The Guidance also addresses the need for an exemption under the Controlled Drugs and Substances Act, if a restricted drug is authorized for sale through the SAP.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada opens consultation on proposed application of definition of Canadian reference product based on Dormant status
On March 27, 2023, Health Canada opened for consultation a proposed application of the definition of Canadian reference product under C.08.001.1(b) of the Food and Drug Regulations.Read More -
Health Canada proposes amendments to the Food and Drug Regulations and Medical Devices Regulations to modernize framework for therapeutic product recalls
On April 15, 2023, Health Canada proposed amendments to the Food and Drug Regulations and the Medical Devices Regulations (together, the “Proposed Amendments”).Read More -
Proposed legislation for patent term adjustment, and the interplay with CSPs
Bill C-47 is an omnibus bill that includes proposed amendments to the Patent Act to introduce patent term adjustment to compensate the patentee for Patent Office delays in granting a patent.Read More